The pathogenesis of T2D includes a progression from chronic insulin resistance and the loss of β-cell mass and function to a resultant inadequate capacity of the β-cells to secrete insulin in sufficient quantities to compensate for the decrease in insulin sensitivity [5,6,7,8,9]. This evidence concerns the gene INS and Insulin resistance.